论著

重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗难治性慢性痛风性关节炎的临床分析

Clinical analysis of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein in refractory chronic gouty arthritis

:1264-1267
 
目的 评估重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白(rhTNRF:Fc)治疗难治性慢性痛风性关节炎的临床疗效及安全性。方法 选取2022年1月一2023年12月广州中医药大学顺德医院风湿科门诊收治的46例难治性痛风性关节炎患者,分为观察组和对照组两组,对照组规范使用降尿酸药物治疗,观察组在对照组治疗的基础上联合使用rhTNRF:Fc至少12周,在0、12、24、48周观察两组的血尿酸(sUA)、肿瘤坏死因子-α(TNF-α)、关节肌肉骨骼超声变化、痛风发作例数、肝肾功能等指标。结果 观察组与对照组sUA无明显差别(P>0.05),TNF-α水平明显下降(P<0.05),滑膜炎、关节积液影像表现减少(P<0.05),痛风发作例数明显减少(P<0.05),观察期间肝肾功能正常,无患者因不良反应退出研究。结论 rhTNRF:Fc对难治性慢性痛风性关节炎安全有效。
Objective To explore the efficacy and safety of recombinant human type II tumor necrosis factor receptor-antibody fusion protein(rhTNRF:Fc)in refractory chronic gouty arthritis. Methods From January 2022 to December 2023, 46 cases of refractory chronic gouty arthritis in the Rheumatology Outpatient Department,Shunde Hospital Guangzhou University of Chinese Medicine were selected and divided into an observation group and a control group. The control group received routine treatment,while the observation group received rhTNRF:Fc treatment additionally for at least 12 weeks, two groups of indicators such as serum urine acid(sUA), TNF-α, changes in musculoskeletal ultrasound,number of gout attacks,hepatic and renal function at 0, 12, 24, and 48 weeks were observed. Results There was no significant difference in sUA between the observation group and the control group(P>0. 05), TNF-α significantly decreased(P<0. 05), synovitis and joint effusion imaging manifestations reduced(P<0. 05), number of gout attacks decreased(P<0. 05). During the observation period, liver and kidney function were normal, and no patients withdrew from the study due to adverse reactions. Conclusions Using rhTNRF:Fc is safe and effective in treating refractory chronic gouty arthritis.
论著

鲁拉西酮治疗女性急性期精神分裂症的疗效及代谢风险观察

Observation of the efficacy and metabolic risk of lurasidone in the treatment of acute schizophrenia in women

:1145-1152
 
        目的   比较鲁拉西酮与奥氮平用于治疗女性急性期精神分裂症患者的疗效,以及其对体质量、糖脂代谢风险的影响。以期为女性急性期的精神分裂症患者抗精神病药物的选择提供参考。方法   连续选取于2022年4月—2024年4月内江门市第三人民医院收治的女性急性期精神分裂症患者80例,采用计算机随机分组法将患者分为治疗组与阳性药物对照组进行对照。治疗组40例口服鲁拉西酮40~80 mg/d,阳性药物对照40例组口服奥氮平5~20 mg/d。分别测量两组治疗前(基线)以及连续用药治疗2、4、6周后的PANSS量表评分,以及治疗后的代谢指标[体质量指数(BMI)、血清空腹血糖(FPG)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A(ApoA)、载脂蛋白B(ApoB)、载脂蛋白E(ApoE),并将治疗组与对照组前后疗效及各项代谢指标进行比较分析。结果   两组的总有效率比较差异无统计学意义(χ 2 =1.569,P>0.05);两组治疗前后PANSS量表评分的时间-组别效应与组别效应均无统计学意义(χ 2 =0.466、3.640,P=0.926、0.056),时间主效应显著(χ 2 =363.24,P<0.001)。两组TG、TC、HDL、ApoA、ApoB存在组别-时间交互效应(χ 2 =7.562、5.991、6.163、6.958、4.397,P=0.006、0.014、0.013、0.008、0.036),两组TG、ApoA时间主效应显著(χ 2 =33.473、8.846,P<0.001、0.003),两组ApoA组别效应显著(χ 2 =4.889,P=0.027)。   与奥氮平相比,鲁拉西酮治疗女性急性期精神分裂症的疗效相当,且对代谢指标影响更小。
        Objective  To compare the efficacy of lurasidone and olanzapine in the treatment of female patients with acute schizophrenia,as well as their effects on body mass,glucose and lipid metabolism risk.To provide  reference for the selection of antipsychotic drugs for female patients with acute schizophrenia.Methods  From April 2022 to April 2024,80 female patients with acute phase schizophrenia admitted to the Third People’s Hospital of Jiangmen City were selected as samples and included in the study.The patients were randomly divided into a treatment group and a positive drug control group using a computer randomization method for comparison.The treatment group took oral lorazepine tablets(40 cases;40-80 mg/d),while the positive drug control group took oral olanzapine tablets(40 cases;5-20 mg/d).The Positive and Negative Symptom Scale(PANSS)scores of two groups before treatment(baseline)and after 2,4,and 6 weeks of continuous medication treatment were measured,as well as metabolic indicators after treatment (body mass index[BMI],serum fasting blood glucose[FPG],total cholesterol[TC],triglycerides[TG],high-density lipoprotein[HDL],low-density lipoprotein[LDL],apolipoprotein A[ApoA],apolipoprotein B[ApoB],apolipoprotein E[ApoE]),and the efficacy and various metabolic indicators between the treatment group and the control group before and after treatment were compared and analyzed.Results  The total effective  rate of the two groups was not statistically significant(χ 2 =1.569,P>0.05).The time-group effect and group effect of PANSS scores before and after treatment in both groups were not statistically significant(χ 2 =0.466,3.640,P=0.926,0.056),while the time main effect was significant(χ 2 =363.24,P<0.001).There was a group-time interaction effect between two groups of TG,TC,HDL,ApoA,and ApoB(χ 2 =7.562,5.991,6.163,6.958,4.397,P=0.006,0.014,0.013,0.008,0.036).The time main effect of TG and ApoA was significant in both groups(χ 2 =33.473,8.846,P<0.001,0.003),and the group effect of ApoA was significant in both groups(χ 2 =4.889,P=0.027).Conclusions  Compared with olanzapine,the efficacy of lurasidone in the treatment of acute phase schizophrenia in women is comparable,and it has a smaller impact on metabolic indicators.
出版者信息








《广州医药》公众号